Microarrays to Identify New Therapeutic Strategies for Cancer

Advances in Cancer Research

Volumn 96, Issue , 2006, Pages 51-74

  Sears, Christopher ^a   Armstrong, Scott A ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DNA METHYLTRANSFERASE; DOCETAXEL; DOXORUBICIN; FLT3 PROTEIN INHIBITOR; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PROTEIN INHIBITOR; TAMOXIFEN; TIPIFARNIB; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; GENE SILENCING; HUMAN; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; THYROID CARCINOMA; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845193373     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)96003-5     Document Type: Review

References (59)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
2. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., and Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30 (2002) 41-47
3. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., Golub T.R., Griffin J.D., et al. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
4. Bidaut G., Suhre K., Claverie J.M., and Ochs M.F. Determination of strongly overlapping signaling activity from microarray data. BMC Bioinform. 7 (2006) 99
5. Boyer J., Allen W.L., McLean E.G., Wilson P.M., McCulla A., Moore S., Longley D.B., Caldas C., and Johnston P.G. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 66 (2006) 2765-2777
6. Brown P., Levis M., Shurtleff S., Campana D., Downing J., and Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105 (2005) 812-820
7. Bullinger L., and Valk P.J. Gene expression profiling in acute myeloid leukemia. J. Clin. Oncol. 23 (2005) 6296-6305
8. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R.F., Tibshirani R., Dohner H., and Pollack J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1605-1616
9. Burczynski M.E., Oestreicher J.L., Cahilly M.J., Mounts D.P., Whitley M.Z., Speicher L.A., and Trepicchio W.L. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr. Mol. Med. 5 (2005) 83-102
10. Callagy G., Pharoah P., Chin S.F., Sangan T., Daigo Y., Jackson L., and Caldas C. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J. Pathol. 205 (2005) 388-396
11. Chiaretti S., Ritz J., and Foa R. Genomic analysis in lymphoid leukemias. Rev. Clin. Exp. Hematol. 9 (2005) E3
12. Clarke P.A., te Poele R., and Workman P. Gene expression microarray technologies in the development of new therapeutic agents. Eur. J. Cancer 40 (2004) 2560-2591
13. Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194 (2001) 1861-1874
14. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
15. Evans W.E., and Relling M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
16. Febbo P.G., Thorner A., Rubin M.A., Loda M., Kantoff P.W., Oh W.K., Golub T., and George D. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin. Cancer Res. 12 (2006) 152-158
17. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
18. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., Pei D., Cheng C., Pui C.H., Relling M.V., Janka-Schaub G.E., Pieters R., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351 (2004) 533-542
19. Jain K.K. Applications of AmpliChip CYP450. Mol. Diagn. 9 (2005) 119-127
20. Krusche C.A., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., Beier H.M., and Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res. Treat. 90 (2005) 15-23
21. Kung C., Kenski D.M., Dickerson S.H., Howson R.W., Kuyper L.F., Madhani H.D., and Shokat K.M. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl. Acad. Sci. USA 102 (2005) 3587-3592
22. Losson R., and Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc. Natl. Acad. Sci. USA 76 (1979) 5134-5137
23. Mallory J.C., Crudden G., Oliva A., Saunders C., Stromberg A., and Craven R.J. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol. Pharmacol. 68 (2005) 1747-1756
24. Maquat L.E. Nonsense-mediated mRNA decay in mammals. J. Cell Sci. 118 (2005) 1773-1776
25. Martens J.W., Nimmrich I., Koenig T., Look M.P., Harbeck N., Model F., Kluth A., Bolt-de Vries J., Sieuwerts A.M., Portengen H., Meijer-Van Gelder M.E., Piepenbrock C., et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65 (2005) 4101-4117
26. Mauriac L., Debled M., and MacGrogan G. When will more useful predictive factors be ready for use?. Breast 14 (2005) 617-623
27. Niyaz Y., Stich M., Sagmuller B., Burgemeister R., Friedemann G., Sauer U., Gangnus R., and Schutze K. Noncontact laser microdissection and pressure catapulting: Sample preparation for genomic, transcriptomic, and proteomic analysis. Methods Mol. Med. 114 (2005) 1-24
28. Rao A.S., Kremenevskaja N., von Wasielewski R., Jakubcakova V., Kant S., Resch J., and Brabant G. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinibmesylate (gleevec) in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 91 (2006) 159-168
29. Richardson A., and Kaye S.B. Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updat. 8 (2005) 311-321
30. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., Yang L., Pickeral O.K., Rassenti L.Z., Powell J., Botstein D., Byrd J.C., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194 (2001) 1639-1647
31. Ross M.E., Mahfouz R., Onciu M., Liu H.C., Zhou X., Song G., Shurtleff S.A., Pounds S., Cheng C., Ma J., Ribeiro R.C., Rubnitz J.E., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104 (2004) 3679-3687
32. Ryden L., Stendahl M., Jonsson H., Emdin S., Bengtsson N.O., and Landberg G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res. Treat. 89 (2005) 135-143
33. Sakakura C., Hasegawa K., Miyagawa K., Nakashima S., Yoshikawa T., Kin S., Nakase Y., Yazumi S., Yamagishi H., Okanoue T., Chiba T., and Hagiwara A. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin. Cancer Res. 11 (2005) 6479-6488
34. Sehn L.H., and Connors J.M. Treatment of aggressive non-Hodgkin's lymphoma: A North American perspective. Oncology (Williston Park) 19 (2005) 26-34
35. Sharma-Oates A., Quirke P., and Westhead D.R. TmaDB: A repository for tissue microarray data. BMC Bioinform. 6 (2005) 218
36. Shia J., Klimstra D.S., Li A.R., Qin J., Saltz L., Teruya-Feldstein J., Akram M., Chung K.Y., Yao D., Paty P.B., Gerald W., and Chen B. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol. 18 (2005) 1350-1356
37. Shibata T., Uryu S., Kokubu A., Hosoda F., Ohki M., Sakiyama T., Matsuno Y., Tsuchiya R., Kanai Y., Kondo T., Imoto I., Inazawa J., et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features. Clin. Cancer Res. 11 (2005) 6177-6185
38. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., Ray T.S., Koval M.A., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8 (2002) 68-74
39. Smith P.G., Wang F., Wilkinson K.N., Savage K.J., Klein U., Neuberg D.S., Bollag G., Shipp M.A., and Aguiar R.C. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 105 (2005) 308-316
40. Stam R.W., den Boer M.L., Schneider P., Nollau P., Horstmann M., Beverloo H.B., van der Voort E., Valsecchi M.G., de Lorenzo P., Sallan S.E., Armstrong S.A., and Pieters R. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106 (2005) 2484-2490
41. Takai N., Kawamata N., Walsh C.S., Gery S., Desmond J.C., Whittaker S., Said J.W., Popoviciu L.M., Jones P.A., Miyakawa I., and Koeffler H.P. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol. Cancer Res. 3 (2005) 261-269
42. Takata R., Katagiri T., Kanehira M., Tsunoda T., Shuin T., Miki T., Namiki M., Kohri K., Matsushita Y., Fujioka T., and Nakamura Y. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11 (2005) 2625-2636
43. Torelli G.F., Guarini A., Porzia A., Chiaretti S., Tatarelli C., Diverio D., Maggio R., Vitale A., Ritz J., and Foa R. FLT3 inhibition in t(4; 11)+ adult acute lymphoid leukaemia. Br. J. Haematol. 130 (2005) 43-50
44. Tovey S., Dunne B., Witton C.J., Forsyth A., Cooke T.G., and Bartlett J.M. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?. Clin. Cancer Res. 11 (2005) 4835-4842
45. Tzankov A., Went P., Zimpfer A., and Dirnhofer S. Tissue microarray technology: Principles, pitfalls and perspectives: Lessons learned from hematological malignancies. Exp. Gerontol. 40 (2005) 737-744
46. Urzua U., Frankenberger C., Gangi L., Mayer S., Burkett S., and Munroe D.J. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol. 26 (2005) 236-244
47. Uttamchandani M., Walsh D.P., Yao S.Q., and Chang Y.T. Small molecule microarrays: Recent advances and applications. Curr. Opin. Chem. Biol. 9 (2005) 4-13
48. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., and Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1617-1628
49. van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 Suppl. 2 (2005) 30-34
50. Wachi S., Yoneda K., and Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21 (2005) 4205-4208
51. Warford A. Tissue microarrays: Fast-tracking protein expression at the cellular level. Expert Rev. Proteomics 1 (2004) 283-292
52. Wilson C., Yang J., Strefford J.C., Summersgill B., Young B.D., Shipley J., Oliver T., and Lu Y.J. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes Cancer 43 (2005) 211-216
53. Wolf M., Edgren H., Muggerud A., Kilpinen S., Huusko P., Sorlie T., Mousses S., and Kallioniemi O. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cell Oncol. 27 (2005) 169-173
54. Yang S.X., Simon R.M., Tan A.R., Nguyen D., and Swain S.M. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin. Cancer Res. 11 (2005) 6226-6232
55. Yao R., Wang Y., Lu Y., Lemon W.J., End D.W., Grubbs C.J., Lubet R.A., and You M. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: Role of Ha-ras mutations and use of microarray analysis to identify potential targets. Carcinogenesis 27 7 (2006) 1420-1431
56. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., Behm F.G., Raimondi S.C., Relling M.V., Patel A., Cheng C., Campana D., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 (2002) 133-143
57. Zheng C., Li L., Haak M., Brors B., Frank O., Giehl M., Fabarius A., Schatz M., Weisser A., Lorentz C., Gretz N., Hehlmann R., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 6 (2006) 1028-1034
58. Zheng P.Z., Wang K.K., Zhang Q.Y., Huang Q.H., Du Y.Z., Zhang Q.H., Xiao D.K., Shen S.H., Imbeaud S., Eveno E., Zhao C.J., Chen Y.L., et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 102 (2005) 7653-7658
59. Zirn B., Hartmann O., Samans B., Krause M., Wittmann S., Mertens F., Graf N., Eilers M., and Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int. J. Cancer 118 (2006) 1954-1962